Consistently, MS patients with high Sema4A levels (≥ 2500 U/ml) exhibit Th17 skewing in peripheral blood mononuclear cells (PBMC) and show significantly more severe Expanded Disability Status Scale (EDSS) score under IFN-β treatment, while fingolimod is effective for those patients [12]. The gene discussed is SEMA4A; the disease is myeloid sarcoma.